# Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers

> **NCT03892161** · PHASE1 · TERMINATED · sponsor: **University of Cape Town** · enrollment: 17 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Darunavir/ritonavir 800/100 mg tablet
- **DRUG:** Rifampicin 600mg QD tablet and DTG 50mg BD

## Key facts

- **NCT ID:** NCT03892161
- **Lead sponsor:** University of Cape Town
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-12
- **Primary completion:** 2018-11-22
- **Final completion:** 2018-11-22
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Risks to participation
- **Last updated:** 2019-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892161, "Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03892161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*